Details for New Drug Application (NDA): 206093
✉ Email this page to a colleague
NDA 206093 describes TETRABENAZINE, which is a drug marketed by Actavis Labs Fl Inc, Ajanta Pharma Ltd, Apotex, Bionpharma, Chartwell Rx, Dr Reddys, Hetero Labs Ltd V, Hikma, Mylan, Slate Run Pharma, and Sun Pharm, and is included in eleven NDAs. It is available from ten suppliers. Additional details are available on the TETRABENAZINE profile page.
The generic ingredient in TETRABENAZINE is tetrabenazine. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the tetrabenazine profile page.
The generic ingredient in TETRABENAZINE is tetrabenazine. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the tetrabenazine profile page.
Summary for 206093
| Tradename: | TETRABENAZINE |
| Applicant: | Apotex |
| Ingredient: | tetrabenazine |
| Patents: | 0 |
Pharmacology for NDA: 206093
| Mechanism of Action | Vesicular Monoamine Transporter 2 Inhibitors |
Medical Subject Heading (MeSH) Categories for 206093
Suppliers and Packaging for NDA: 206093
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TETRABENAZINE | tetrabenazine | TABLET;ORAL | 206093 | ANDA | Golden State Medical Supply, Inc. | 51407-480 | 51407-480-12 | 112 TABLET in 1 BOTTLE (51407-480-12) |
| TETRABENAZINE | tetrabenazine | TABLET;ORAL | 206093 | ANDA | Golden State Medical Supply, Inc. | 51407-481 | 51407-481-12 | 112 TABLET in 1 BOTTLE (51407-481-12) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 12.5MG | ||||
| Approval Date: | Mar 17, 2020 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Mar 17, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
